Previous 10 | Next 10 |
Cancer Genetics (NASDAQ: CGIX ) -16% . More news on: Cancer Genetics, Inc., Smith & Wesson Brands, Inc., Sonnet BioTherapeutics Holdings, Inc., Stocks on the move, , Read more ...
Certain COVID-19 vaccine developers are under modest pressure premarket on reports that the Trump administration is pushing for early approval of a COVID-19 vaccine, potentially based on a smaller dataset that the 30K subjects that the FDA has stated will be necessary for sign-off. More ...
Quite a few stocks of companies developing COVID-19 therapies and vaccines have soared this year. Some have delivered downright astronomical gains. Don't think for a second that the prospects for bigger returns in the future have diminished. Actually, it seems likely that clinical progress over...
Investing in companies with COVID-19 pipeline candidates, both treatments and vaccines, has been a winner since March but there is a near-certainty of rough seas next month and beyond when companies release results from ongoing studies and new large-scale trials. More news on: Gilead Scien...
The world is in desperate need for a pandemic treatment -- anything to halt the spread. Thousands of people are being infected by the day. Thousands have died. Medical experts have urged President Trump, Congress, and states to shut down again. Schools around the country have opted for anothe...
Come up with a pill that could end the worst health crisis in over a century, and you might find investors scrambling to buy your company's stock. That's exactly what's been going on with small-cap biotech stock Vaxart (NASDAQ: VXRT) , and investors who owned the stock at the beginning of the...
FinancialBuzz.com News Commentary New York, NY (8/17/2020) – Infectious diseases are caused by pathogenic microorganisms such as bacteria, viruses, fungi and parasites, and can be transmitted by direct or indirect contact. Globally, infectious diseases such as malaria, HIV, tuberculosis...
If you bought shares of Altimmune , (NASDAQ: ALT) Vaxart , (NASDAQ: VXRT) or Novavax (NASDAQ: NVAX) at the start of this year, you're already well on your way to riches. Thanks to the market's coronavirus vaccine frenzy, each of these companies' stock prices has exploded by more than 1...
The CV-19 pandemic shows no signs of slowing. To date, there are nearly 21 million cases, with 769,235 deaths. In the U.S., cases are up to 5.25 million. Brazil is up to 3.22 million. India is nearing 2.5 million. Russia is now up to 910,778. Meanwhile, the World Health Organization has warne...
NEW YORK , Aug. 13, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding possible breaches of fiduciary duties related to whether insiders caused their companies to make fals...
News, Short Squeeze, Breakout and More Instantly...
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and noroviru...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per ...